Mechanism of Hypercalcemia in Multiple Myeloma
Hypercalcemia in multiple myeloma is primarily caused by excessive bone resorption driven by local osteoclast activation, with the process measurable through serum bone turnover markers including β-carboxy-terminal cross-linking telopeptide of type I collagen (β-CTX) and procollagen I N-terminal peptide (PINP). 1
Primary Pathophysiologic Mechanism
The dominant mechanism is local osteolytic hypercalcemia (LOH) resulting from:
- Osteoclast activation by myeloma cells releasing cytokines, particularly macrophage inflammatory protein-1α (MIP-1α), which directly stimulates bone resorption 2, 3
- Excessive calcium release from bone destruction into the bloodstream 1
- This represents a fundamentally different process than the humoral hypercalcemia seen in solid tumors
Secondary Humoral Mechanism (Uncommon)
While rare, some myeloma patients develop humoral hypercalcemia of malignancy (HHM) through:
- Secretion of parathyroid hormone-related peptide (PTHrP) by myeloma plasma cells 3, 4, 5
- This mechanism can coexist with local bone destruction, potentially causing more severe hypercalcemia 3
- PTHrP increases both renal calcium reabsorption and bone resorption 5
Serum Tests to Measure the Process
Bone Turnover Markers (Primary Tests)
The most direct measures of the bone resorption process include:
- β-carboxy-terminal cross-linking telopeptide of type I collagen (β-CTX) - elevated in hypercalcemic myeloma patients 2
- Procollagen I N-terminal peptide (PINP) - elevated in hypercalcemic myeloma patients 2
- Osteocalcin - elevated in hypercalcemic myeloma patients 2
- Urinary deoxypyridinoline - marker of bone resorption 5
Mechanistic Differentiation Tests
To distinguish between local osteolytic and humoral mechanisms:
- Parathyroid hormone-related peptide (PTHrP) - elevated only when humoral mechanism is present (normal <1.1 pmol/L) 3, 5
- Intact parathyroid hormone (i-PTH) - typically suppressed in myeloma-related hypercalcemia 2, 5
- Macrophage inflammatory protein-1α (MIP-1α) - elevated when local bone destruction predominates (normal <46.9 pg/mL) 3
- Nephrogenous cyclic AMP - elevated when PTHrP mechanism is active 5
Standard Calcium Assessment
- Ionized calcium - the physiologically active form, essential for accurate diagnosis especially in patients with abnormal albumin or paraprotein levels 6
- Corrected total calcium - must account for hypoalbuminemia common in myeloma 7
Clinical Correlation
Important caveat: Patients with hypercalcemia at myeloma diagnosis demonstrate significantly worse outcomes, with median survival of 40 months versus 57 months in normocalcemic patients 2. The presence of hypercalcemia correlates with:
- Higher β2-microglobulin and creatinine levels
- Lower hemoglobin and PTH levels
- Advanced ISS and R-ISS stages
- Higher bone turnover marker levels 2
Severe hypercalcemia (≥3.5 mmol/L or ≥14 mg/dL) is an independent risk factor for both overall survival and progression-free survival 7, making rapid identification and correction critical.
Pseudohypercalcemia Warning
Be aware that hypergammaglobulinemia in myeloma can cause falsely elevated total calcium through enhanced calcium binding to circulating globulins 6. When total calcium is elevated but clinical suspicion is low:
- Measure ionized calcium directly
- Consider PEG precipitation testing
- Verify with alternative methods (ICP-MS) if available 6
The NCCN guidelines emphasize that excess bone resorption leads to excessive calcium release, and treatment should include hydration, bisphosphonates (preferably zoledronic acid), denosumab, steroids, and/or calcitonin 1.